
    
      Nimotuzumab and Irinotecan will be administered to the patient until disease progression or
      development of toxicity preclude further treatment.Irinotecan will be administered once every
      14 days,the dosage is 180mg/m2; Nimotuzumab treatment be divided 3
      levels:200mg/w,400mg/w,600mg/w,weekly.The patients'blood test and liver and renal function
      tests will be monitored weekly, a physical exam and reassessment of the tumor will be
      performed and every 6 weeks,when the total result is the CR or PR, the result of the 6th and
      the 12th week should be compared.
    
  